Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral Diabetic Neuropathy Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 25, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

NCT04678895
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 11:03 PM EDT
Not listed Phase 2 Interventional

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

NCT04679545
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBD, Placebo
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomfield Township, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

NCT00381719
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
AGN 203818, placebo capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Sep 25, 2026, 11:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy

NCT01695629
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 4 Interventional

Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies

NCT02842554
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN)
Interventions
EPT, Drug Placebo Administration, C
Other · Drug
Lead sponsor
Analgesic Solutions
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 25, 2026, 11:03 PM EDT
Completed No phase listed Observational

The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction

NCT00919347
View directory record Official record
Conditions
Cardiovascular Autonomic Neuropathy, Diabetic Autonomic Neuropathy, Autonomic Dysfunction
Interventions
ANSAR ANX 3.0 Software
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 25, 2026, 11:03 PM EDT
Not listed Not applicable Interventional

Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers

NCT00446472
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Regranex®, Hydrogel
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Long Beach, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Sep 25, 2026, 11:03 PM EDT
Enrolling by invitation Not applicable Interventional

Medtronic Inceptiv™ Closed-Loop DTM Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy

NCT07209514
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN)
Interventions
Implantable SCS with Closed Loop mechanism
Device
Lead sponsor
TriCity Research Center
Industry
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Grand Island, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 25, 2026, 11:03 PM EDT
Not listed No phase listed Observational

Ambulation as a Factor on Oscillating Thermometry

NCT03907189
View directory record Official record
Conditions
Diabetic Neuropathy Peripheral
Interventions
Not listed
Lead sponsor
Podimetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy

NCT03195868
View directory record Official record
Conditions
Neuropathy, Neuropathy, Diabetic, Neuropathy Toxic
Interventions
Realief Therapy
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

NCT00113620
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
Neurodex
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
44
States / cities
Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 4 Interventional

Anodyne Therapy in Diabetic Sensory Neuropathy

NCT00120341
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Neuropathy
Interventions
Anodyne Therapy System
Device
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
25 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2007 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Pilot Study of Exercise and Peripheral Nerve Function in People With Diabetes - ENRGy2 Addendum

NCT01764373
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Aerobic Exercise
Other
Lead sponsor
University of Kansas
Other
Eligibility
40 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Dermal Thermometry and Self-Care of High Risk Diabetic Patients

NCT00105755
View directory record Official record
Conditions
Diabetes Mellitus, Ulcer, Diabetic Polyneuropathy
Interventions
personal dermal thermometer (DT), Device
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Tucson, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 2 Interventional

Dose-effect of SSR180575 in Diabetic Neuropathy

NCT00502515
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
SSR180575, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 25, 2026, 11:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 25, 2026, 11:03 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT01079325
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 22, 2022 · Synced Sep 25, 2026, 11:03 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 25, 2026, 11:03 PM EDT
Completed No phase listed Observational

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

NCT07005947
View directory record Official record
Conditions
Long COVID-19, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
Interventions
Not listed
Lead sponsor
CND Life Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 25, 2026, 11:03 PM EDT
Not listed Not applicable Interventional

An Evaluation of an SCCD on the Symptomatology of Painful DPN

NCT03331614
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Flowaid FA-100 SCCD
Device
Lead sponsor
Rosenblum, Jonathan I., DPM
Individual
Eligibility
18 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lodi, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 11:03 PM EDT